領航醫藥生物科技(00399.HK)擬折讓20%配售9000萬股 總籌2808萬港元補充營運資金
格隆匯7月16日丨領航醫藥生物科技(00399.HK)發佈公告,2025年7月15日,公司與認購人A(即張彪兵)訂立認購協議A,據此,認購人A有條件同意認購而公司有條件同意配發及發行合共6000萬股股份,認購價A爲每股認購股份A0.312港元。認購價A較7月15日(即認購協議A日期)在聯交所所報的收市價每股0.39港元折讓約20%。認購股份A將根據一般授權配發及發行。認購股份A佔本公告日期現有全部已發行股本約3.00%;及經發行認購股份擴大後全部已發行股本約2.92%。
同日,公司與認購人B(即陳靜)訂立認購協議B,據此,認購人B有條件同意認購而公司有條件同意配發及發行合共3000萬股股份,認購價B爲每股認購股份B0.312港元。認購股份B將根據一般授權配發及發行。認購股份B佔本公告日期現有全部已發行股本約1.50%;及經發行認購股份擴大後全部已發行股本約1.48%。
公司將向聯交所申請批準認購股份於聯交所上市及買賣。該等認購事項所得款項總額及所得款項淨額將分別爲約2808萬港元及2778萬港元,擬用作集團的一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.